This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care
treatment of non-small cell lung cancer (NSCLC) in adults. All subjects will receive
high-dose ascorbate in addition to the standard treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Joseph J. Cullen, MD, FACS University of Iowa
Collaborators:
Holden Comprehensive Cancer Center McGuff Pharmaceuticals, Inc. National Cancer Institute (NCI) National Institutes of Health (NIH)